Research Article

Magnetic Resonance of Rectal Cancer Response to Therapy: An Image Quality Comparison between 3.0 and 1.5 Tesla

Damiano Caruso, Marta Zerunian, Domenico De Santis, Tommaso Biondi, Pasquale Paolantonio, Marco Rengo, Davide Bellini, Riccardo Ferrari, Maria Ciolina, Elena Lucertini, Michela Polici, Elsa Iannicelli, Vincenzo Tombolini, and Andrea Laghi

1Department of Medical-Surgical and Translational Medicine-Radiology Unit, “Sapienza” University of Rome, Sant’Andrea Hospital, Rome, Italy
2Department of Radiological, Oncological and Pathological Sciences, “Sapienza” University of Rome, ICOT Hospital, Latina, Italy
3Department of Radiotherapy, “Sapienza” University of Rome, Policlinico Umberto I, Rome, Italy

Correspondence should be addressed to Damiano Caruso; damiano.caruso@uniroma1.it

Received 29 July 2020; Revised 20 September 2020; Accepted 22 September 2020; Published 12 October 2020

Academic Editor: Cristina Grippaudo

Copyright © 2020 Damiano Caruso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To evaluate signal intensity (SI) differences between 3.0 T and 1.5 T on T2-weighted (T2w), diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) in rectal cancer pre-, during, and postneoadjuvant chemoradiotherapy (CRT). Materials and Methods. 22 patients with locally advanced rectal cancer were prospectively enrolled. All patients underwent T2w, DWI, and ADC pre-, during, and post-CRT on both 3.0 T MRI and 1.5 T MRI. A radiologist drew regions of interest (ROIs) of the tumor and obturator internus muscle on the selected slice to evaluate SI and relative SI (rSI). Additionally, a subanalysis evaluating the SI before and after-CRT (ΔSI pre-post) in complete responder patients (CR) and nonresponder patients (NR) on T2w, DWI, and ADC was performed. Results. Significant differences were observed for T2w and DWI on 3.0 T MRI compared to 1.5 T MRI pre-, during, and post-CRT (all P < 0.001), whereas no significant differences were reported for ADC among all controls (all P > 0.05). rSI showed no significant differences in all the examinations for all sequences (all P > 0.05). ΔSI showed significant differences between 3.0 T and 1.5 T MRI for DWI-ΔSI in CR and NR (188.39 ± 166.90 vs. 30.45 ± 21.73 and 169.70 ± 121.87 vs. 22.00 ± 31.29, respectively, all P 0.02) and ADC-ΔSI for CR (−0.58 ± 0.27 vs. −0.21 ± 0.424 value 0.02), while no significant differences were observed for ADC-ΔSI in NR and both CR and NR for T2w-ΔSI. Conclusion. T2w-SI and DWI-SI showed significant differences for 3.0 T compared to 1.5 T in all three controls, while ADC-SI showed no significant differences in all three controls on both field strengths. rSI was comparable for 3.0 T and 1.5 T MRI in rectal cancer patients; therefore, rectal cancer patients can be assessed both at 3.0 T MRI and 1.5 T MRI. However, a significant DWI-ΔSI and ADC-ΔSI on 3.0 T in CR might be interpreted as a better visual assessment in discriminating response to therapy compared to 1.5 T. Further investigations should be performed to confirm future possible clinical application.

1. Introduction

In the last decade, magnetic resonance imaging (MRI) has assumed a crucial role in the local staging of primary and recurrent rectal cancer. Due to its high spatial and contrast resolution, MRI allows not only for tumor and nodal staging but also provides essential information, such as extramural vascular invasion and grade of tumor regression, which help in assessing disease-free survival and overall survival rates [1, 2]. Several studies have extensively investigated the role of 1.5-Tesla (T) MRI in rectal cancer as a robust and accurate imaging modality for preoperative local staging [3–8]. MRI is particularly accurate in assessing the distance between the tumor and the mesorectal fascia with sensitivity and specificity up to 94% and 76%, respectively [9, 10]. Theoretically, 3.0 T MRI achieves a twofold increase of signal-to-noise ratio (SNR) compared to 1.5 T systems due to the dependence of MRI signal to the magnetic field...
strength, resulting in improved spatial and temporal resolution [11–14].

Few studies have assessed patients with rectal cancer by means of 3.0 T MRI and 1.5 T MRI [11, 12, 15, 16]. In particular, Maas et al. [15] have shown that 3.0 T and 1.5 T MRI scanners have similar staging performances independently from the reader expertise; nevertheless, more studies ought to be performed, in particular evaluating quantitative imaging parameters to deepen the comparison between the two field strengths.

Thus, the aim of this work is to compare image quality of 1.5 T and 3.0 T in terms of signal intensity (SI) values in T2-weighted (T2w), DWI sequences, and apparent diffusion coefficient maps (ADC) in some patients with rectal cancer pre-, during, and postneoadjuvant chemoradiotherapy (CRT).

2. Materials and Methods

2.1. Study Population. After the approval of institutional ethics committee, all patients selected have accepted and signed the written informed consent.

Within the Italian Association for Cancer Research (AIRC) prospective trial study “MR Imaging Biomarkers in Response Evaluation to Neoadjuvant Chemoradiotherapy in Rectal Cancer” I.G. 2013, 90 consecutive nonrandomized patients were enrolled between February 2014 and October 2016. For the specific purpose of the study, we included 22 patients who accepted to undergo a second MRI.

Inclusion criterion was the presence of histologically confirmed stage II (cT3–4, N0, M0) or stage III (cT1–4, N+, M0) colorectal adenocarcinoma. Exclusion criteria were as follows: (a) implanted electrical devices or metallic foreign bodies incompatible with MRI, (b) incomplete MRI protocol or histopathological data, (c) contraindication to the use of neoadjuvant CRT or surgical treatment or suspension of neoadjuvant treatment before undergoing surgery, (d) coexistence of other known tumors and/or previous pelvic radiotherapy, (e) proven medical history of hypersensitivity to the drug used in the study or to their excipients, and (f) simultaneous enrollment in other experimental clinical trials and consequent administration of experimental drugs within 30 days of joining this study.

2.2. Study Protocol. Patients underwent both 3.0 T and 1.5 T MRI examinations at three different moments of the trial, already described in another study part of the major project protocol [8]: (a) at the beginning for the locoregional staging, before treatment initiation; (b) during neoadjuvant CRT; and (c) at the end of CRT. To reduce time-related variability of the tumor burden, a time span of 24 hours was set to separate the two MRI examinations at each moment.

2.3. MR Examinations. All the MRI examinations were performed without bowel preparation, rectal distention, or anti-peristaltic agents. Acquisitions were obtained in feet supine position during free breathing. Detailed MRI protocol is reported in Table 1. 3.0 T MRI examinations were performed with a Discovery MR750 scanner (General Electrics, Milwaukee, WS, US), using 16-channel body coil. A routine imaging protocol for local staging of rectal cancer was performed including high-resolution T2-weighted fast recovery fast-spin echo sequence (2D FRFSE) (TR, 2086–4172 ms; TE, 11.4–122.3 ms; acceleration factor (Nex), 2; slice thickness, 4 mm; and matrix, 512 × 512 pixels) acquired on sagittal, transversal, and coronal axes. Additional oblique axial and coronal sequences were oriented, respectively, orthogonal and parallel to the long axis of the tumor. DWI sequences were also performed using a single-shot echoplanar imaging sequence with spectral adiabatic inversion recovery fat saturation technique (TR, 4400 ms; TE, 81.4 ms; Nex, 2; slice thickness, 4 mm; matrix, 256 × 256 pixels; and b values 0–200–600–800–1000 s/mm²), along the three orthogonal directions of the motion-probing gradients.

All patients underwent further MRI scan at a 1.5 T system Magnetom Avanto (Siemens Medical Solutions, Erlangen, Germany), using a 6-channel body coil. Routinely imaging protocol used for local staging of rectal cancer was applied including: oblique T2-weighted high-resolution images (axial and coronal)-oriented perpendicular and parallel to the tumor axis, respectively (TR, 3380 ms; TE, 90 ms; Nex, 2; slice thickness, 5 mm; and matrix, 366 × 448 pixels) and axial single-shot epi-DWI sequences (TR, 6000 ms; TE, 75 ms; Nex, 2; slice thickness, 5 mm; matrix, 168 × 224 pixels; and b values 0–400–800–1000 s/mm²). ADC maps in a gray scale were automatically extrapolated by the operating system. For the purpose of the study, only the oblique axial T2-weighted, DWI sequences, and ADC maps were analyzed.

2.4. Image Analysis. Images were analyzed by means of a workstation (Advantage Workstation 4.4, GE Healthcare, Milwaukee, WI) with a dedicated software (Volume Share 4), in a reporting room equipped with artificial environmental lighting (40 lx). An expert radiologists (AL) with 19 years of experience in oncologic gastrointestinal MRI imaging, with full access to clinical and histological patients’ data, selected a single slice for sequence providing the best tumor depiction at oblique axial T2w, DWI, and ADC maps. The reader paid attention to select the same rectal level for each slice in order to maintain the same evaluation standard for the further analysis.

Once the slices were selected and anonymized, two expert radiologists in consensus (MC and DDS with 11 and 8 years of experience in rectal MRI, respectively) assessed the objective image quality blinded to the field strength, timeline of MRI examinations, and pathologic results. Images were grouped in stacks of 12 each and presented in random order for a total of 33 reading sections. A three-day time interval was set between each reading section.

A circular region of interest (ROI, mean size: 65 mm²; range, 50–75 mm²) was placed in consensus by the two readers in the lesions on T2w, DWI at 1000 b values, and ADC maps (Figure 1), carefully avoiding the rectal lumen, healthy rectal wall (in case of eccentric cancer), and mesorectal fat. For images with no obvious high SI representing the tumor, the three ROIs where placed within the apparent tumor where the residual tissue was visible even if hypointense and fibrotic. Additional circular ROIs (mean size: 65 mm²; range, 50–75 mm²) were placed in the right internus obturator muscle. All measurements were performed three
times and eventually averaged. SI of each ROI was recorded, and relative SI (rSI) was normalized as follows:

\[ rSI = \frac{SI_{\text{tumor}}}{SI_{\text{muscle}}} \]  

Furthermore, according to pathology, a subanalysis on complete responders (CR) and nonresponders (NR) was performed, calculating a \( \Delta \) between the tumor SI before and after CRT, both at 3.0 T MRI and 1.5 T MRI, as follows:

\[ \Delta SI = SI_{\text{pre-CRT}} - SI_{\text{post-CRT}} \]  

2.5. Statistical Analysis. Statistical analysis was performed using MedCalc Statistical Software version 17.9.7 (MedCalc Software bvba, Ostend, Belgium).

All data are expressed as mean ± standard deviation (SD). Data distribution was assessed with the Kolmogorov-Smirnov test. In case of Gaussian distribution, data were tested with Student's \( t \) -test, while Wilcoxon's test was applied for non-Gaussian distributed data. A two-sided \( P \) value < 0.05 was considered statistically significant.

3. Results

3.1. Patient Population. Detailed patient characteristics are reported in Table 2. From an initial population of 90 patients, 68 were excluded due to incomplete MRI protocol at the time of the patients' selection \( (n = 20) \), noncompletion of the CRT at the time of the enrollment for the present study \( (n = 46) \), and unperformed surgical treatment \( (n = 2) \). Thus, the final population consisted of 22 patients \( (11 \text{ men}; \text{mean age: } 65.59 \pm 8.72; \text{age range 48-81}) \), as shown in the flowchart below (Figure 2).
On the basis of the MRI scans, 1 patient (4%) was diagnosed with local tumor staging of T2, 14 patients (63%) were diagnosed with T3, and 7 (31%) had a T4 rectal cancer, following the radiological staging UICC 2009 of I for 1 patient, IIA for 6 patients, IIB for 9 patients, and III C for 6 patients.

All patients underwent total mesorectal excision. The pathological evaluation found complete response in 9 patients (41%), partial response in 5 patients (23%), and no response in 8 patients (36%).

### Table 3: Signal intensity values on 3.0 T and 1.5 T pre-, during, and post-CRT.

|            | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                |
|------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Pre-CRT    | 632.60 ± 183.02      | 341.88 ± 120.98      | <0.0001*             | 321.32 ± 176.99      | 70.77 ± 21.44        | <0.0001*             | 1.05 ± 0.22          | 1.07 ± 0.26          | 0.75                 |                       |                      |
| During CRT | 511.85 ± 193.59      | 318.23 ± 107.77      | 0.0011*              | 184.35 ± 95.47       | 51.47 ± 17.00        | <0.0001*             | 1.40 ± 0.28          | 1.33 ± 0.30          | 0.51                 |                       |                      |
| Post-CRT   | 525.08 ± 149.67      | 293.68 ± 99.17       | <0.0001*             | 136.33 ± 70.03       | 43.52 ± 14.84        | <0.0001*             | 1.55 ± 0.35          | 1.45 ± 0.32          | 0.41                 |                       |                      |

*Significant P values.

### Table 4: Relative signal intensity values on 3.0 T and 1.5 T pre-, during, and post-CRT.

|            | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                | 3.0 T                | 1.5 T                |
|------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Pre-CRT    | 2.99 ± 0.77          | 4.60 ± 4.84          | 0.14                 | 4.80 ± 1.71          | 4.84 ± 1.40          | 0.95                 | 4.90 ± 12.75         | 2.16 ± 0.98          | 0.07                 |                      |
| During CRT | 2.91 ± 1.24          | 3.42 ± 1.15          | 0.11                 | 3.30 ± 0.95          | 3.37 ± 1.01          | 0.79                 | 1.70 ± 0.99          | 2.02 ± 0.87          | 0.18                 |                      |
| Post-CRT   | 2.30 ± 0.93          | 2.73 ± 1.03          | 0.14                 | 2.91 ± 1.43          | 2.48 ± 0.76          | 0.78                 | 1.85 ± 0.95          | 1.97 ± 0.73          | 0.16                 |                      |

*Significant P values.

3.2. Image Analysis. Full results are reported in Tables 3, 4, and 5. 3.0 T MRI provided significantly higher tumor SI at T2w sequences (all $P \leq 0.001$), and DWI (all $P < 0.001$) compared to 1.5 T at each imaging control, while no statistically significant differences were reported for ADC values between 3.0 T and 1.5 T (all $P \geq 0.41$). In addition, no statistically significant differences were found between 3.0 T and 1.5 T in terms of rSI for T2w (all $P \geq 0.11$), DWI (all $P \geq 0.78$), and ADC maps (all $P \geq 0.07$) at each imaging control.
The subanalysis performed comparing ΔSI on 3.0 T MRI and 1.5 T MRI in complete responder patients (Figure 3) showed significant differences for DWI-ΔSI (188.39 ± 166.90 vs. 30.45 ± 21.73; \( P = 0.02 \)) and ADC-ΔSI (−0.58 ± 0.27 vs. −0.21 ± 0.24; \( P = 0.02 \)), while no significant differences were observed for T2w-ΔSI (149.89 ± 211.92 vs. 133.64 ± 116.80; \( P = 0.87 \)). The subanalysis of ΔSI between 3.0 T and 1.5 T was also performed for NR showing significant differences for DWI-ΔSI (188.39 ± 166.90 vs. 30.45 ± 21.73; \( P = 0.02 \)); no significant differences were observed for ADC-ΔSI and T2w-ΔSI (−0.58 ± 0.36 vs. −0.44 ± 0.25 and 57.15 ± 224.02 vs. −57.26 ± 133.12, respectively; all \( P > 0.31 \)).

### 4. Discussion

This study quantitatively compared SI on 3.0 T MRI and 1.5 T MRI in patients with rectal cancer before, during, and after CRT, aimed at assessing the impact of magnetic field strength in the diagnosis and follow-up. Our results showed that 3.0 T scanner provided significantly higher SI on T2w and DWI compared to 1.5 T scanner, while no significant differences in terms of ADC maps have been reported. Interestingly, the two scanners provided similar results in terms of relative signal intensity at every sequence. A possible explanation of this phenomenon could be the fact that higher magnetic fields are more susceptible to motion artifacts compared to lower magnetic fields. In fact, the absolute signal intensity can be influenced by many external and intrinsic factors, such as rectal peristalsis in the pelvic region. Thus, the signal normalization to a stable landmark, such as the obturator internus muscle, making rSI more standardized compared to absolute SI values [16, 17]. These results may lead to an important consideration: the added value of 3.0 T MRI scanner compared to 1.5 T MRI scanner in the evaluation of rectal cancer signal intensity may be questionable, also in accordance with the latest recommendations of the European Society of Gastrointestinal and Abdominal Radiology [18], which do not identify any of the two magnetic fields as the recommended imaging modality in the non-invasive assessment of rectal cancer. Interestingly, similar conclusions have been drawn by Ullrich et al. [17] for prostate MRI examination. The authors demonstrated similar objective image quality for T2w images at 3.0 T and 1.5 T scanners, ultimately leading to comparable diagnostic performances and Prostate Imaging Reporting and Data System (PI-RADS) score at both field strengths. Regarding a similar study on rectal cancer, Cai et al. [16] reported significantly higher diagnostic performance for normalized DWI at 3.0 T instead of 1.5 T; however, their results cannot be compared with the ones from our study that was focused on quantitative evaluation of SI and rSI instead of diagnostic performance.

### Table 5: Δ signal intensity values pre-post-CRT on 3.0 T and 1.5 T.

(a) Complete responder patients

|        | Pre-CRT  | 3.0 T Post-CRT | ΔSI | Pre-CRT  | 1.5 T Post-CRT | ΔSI | \( P \) |
|--------|----------|----------------|-----|----------|----------------|-----|--------|
| T2w    | 720.38 ± 232.91 | 570.49 ± 138.21 | 149.89 ± 211.92 | 401.61 ± 163.09 | 267.97 ± 120.55 | 133.64 ± 116.80 | 0.87   |
| DWI    | 313.23 ± 181.74 | 124.84 ± 21.54  | 188.39 ± 166.90 | 66.73 ± 27.03   | 36.29 ± 8.21     | 30.45 ± 21.73   | 0.02*  |
| ADC    | 1.08 ± 0.24   | 1.67 ± 0.33     | −0.58 ± 0.27    | 1.17 ± 0.28      | 1.38 ± 0.28       | −0.21 ± 0.24    | 0.02*  |

*Significant \( P \) values.

(b) Nonresponder patients

|        | Pre-CRT  | 3.0 T Post-CRT | ΔSI | Pre-CRT  | 1.5 T Post-CRT | ΔSI | \( P \) |
|--------|----------|----------------|-----|----------|----------------|-----|--------|
| T2w    | 559.42 ± 128.60 | 502.28 ± 176.81 | 57.15 ± 224.02 | 283.21 ± 66.36 | 340.47 ± 96.31 | −57.26 ± 133.12 | 0.31   |
| DWI    | 291.18 ± 140.89 | 121.48 ± 53.70  | 169.70 ± 121.87 | 69.15 ± 20.35  | 47.15 ± 17.99   | 22.00 ± 31.29   | 0.02*  |
| ADC    | 1.04 ± 0.19   | 1.62 ± 0.33     | −0.58 ± 0.36    | 1.12 ± 0.22     | 1.56 ± 0.23      | −0.44 ± 0.25    | 0.46   |

*Significant \( P \) values.
Our results indicate that 3.0 T MRI scanner may outperform the 1.5 T MRI system in the visual assessment of rectal cancer in complete responder patients. Despite Maas et al. [15] demonstrating that 3 T and 1.5 T reached the same performance in rectal cancer staging, in our study, the higher ΔSI of DWI and ADC of 3.0 T between the beginning and the completion of CRT in such patients may ultimately increase the visual assessment and readers' confidence in ruling out the presence of residual viable tissue at the end of CRT. On the other hand, at 1.5 T MRI examinations, a minimal residual restriction could be misdiagnosed as incomplete response to therapy (Figure 4).

This investigation should be evaluated taking into account some limitations. First, this preliminary investigation had a small sample size and is aimed at comparing quantitative MRI parameters in rectal cancer. The assessment of diagnostic performances was beyond our study design and further large prospective trials are advisable. Second, image analysis was performed on a single slice rather than on the whole tumor volume. Third, the comparative study was performed between two different vendors. Forth, due to the consensus reading of the selected slices, interreader agreement could not be performed.

In conclusion, despite significant differences of SI on T2w and DWI between 3.0 T and 1.5 T, the relative SI analysis...
showed similar results for both field strengths; therefore, per single examination, rectal cancer patients can be assessed both at 3.0 T MRI and 1.5 T MRI. However, DWI-ΔSI and ADC-ΔSI on 3.0 T reveals better results compared to 1.5 T in the response to treatment assessment and should be further investigated in a larger cohort of patients to verify this result and its possible clinical application.

**Abbreviations**

ADC: Apparent diffusion coefficient maps  
CR: Complete responder patients  
CNR: Contrast-to-noise ratio  
DWI: Diffusion-weighted imaging  
FOV: Field of view  
2D FRFSE: High-resolution T2-weighted fast recovery fast-spin echo sequence  
MRI: Magnetic resonance imaging  
CRT: Neoadjuvant chemoradiotherapy  
NR: Nonresponder patients  
PR: Partial responder patients  
RF: Radiofrequency  
ROI: Region of interest  
rSI: Relative signal intensity  
SI: Signal intensity  
SNR: Signal-to-noise ratio  
SD: Standard deviation  
T2w: T2-weighted  
T: Tesla.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Disclosure**

An earlier version of this research has been presented at European Congress of Radiology 2019 during the scientific session SS 1501a "Rectal cancer: what’s new?" (number of presentation: B-1341).

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

This study was supported by AIRC Foundation (2013/14129).

**References**

[1] S. Balyasnikova and G. Brown, “Optimal imaging strategies for rectal cancer staging and ongoing management,” *Current Treatment Options in Oncology*, vol. 17, no. 6, p. 32, 2016.

[2] H. Kim, J. S. Lim, J. Y. Choi et al., "Rectal cancer: comparison of accuracy of local-regional staging with two- and three-dimensional preoperative 3-T MR imaging," *Radiology*, vol. 254, no. 2, pp. 485-492, 2010.

[3] G. Brown, A. G. Radcliffe, R. G. Newcombe, N. S. Dallimore, M. W. Bourne, and G. T. Williams, "Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging," *The British Journal of Surgery*, vol. 90, no. 3, pp. 355–364, 2003.

[4] G. Brown, I. R. Daniels, C. Richardson, P. Revell, D. Peppercorn, and M. Bourne, "Techniques and troubleshooting in high spatial resolution thin slice MRI for rectal cancer," *The British Journal of Radiology*, vol. 78, no. 927, pp. 245-251, 2005.

[5] G. Brown, A. Kirkham, G. T. Williams et al., "High-resolution MRI of the anatomy important in total mesorectal excision of the rectum," *AJR American Journal of Roentgenology*, vol. 182, no. 2, pp. 431–439, 2004.

[6] D. Caruso, M. Zerunian, M. Ciolina et al., “Haralick’s texture features for the prediction of response to therapy in colorectal cancer: a preliminary study,” *La Radiologia Medica*, vol. 123, no. 3, pp. 161-167, 2018.

[7] M. Ciolina, D. Caruso, D. de Santis et al., “Dynamic contrast-enhanced magnetic resonance imaging in locally advanced...
rectal cancer: role of perfusion parameters in the assessment of response to treatment,” *La Radiologia Medica*, vol. 124, no. 5, pp. 331–338, 2019.

[8] C. N. De Cecco, B. Ganeshan, M. Ciolina et al., “Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance,” *Investigative Radiology*, vol. 50, no. 4, pp. 239–245, 2015.

[9] R. G. H. Beets-Tan, G. L. Beets, R. F. A. Vliegen et al., “Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery,” *Lancet*, vol. 357, no. 9255, pp. 497–504, 2001.

[10] S. Bipat, A. S. Glas, F. J. M. Slors, A. H. Zwinderman, P. M. M. Bossuyt, and J. Stoker, “Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis,” *Radiology*, vol. 232, no. 3, pp. 773–783, 2004.

[11] J. Y. Choi, M. J. Kim, Y. E. Chung et al., “Abdominal applications of 3.0-T MR imaging: comparative review versus a 1.5-T system,” *Radiographics*, vol. 28, no. 4, article e30, 2008.

[12] L. M. Wu, J. Zhu, J. Hu et al., “Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer?,” *International Journal of Colorectal Disease*, vol. 28, no. 9, pp. 1225–1238, 2013.

[13] K. J. Chang, I. R. Kamel, K. J. Macura, and D. A. Bluemke, “3.0-T MR imaging of the abdomen: comparison with 1.5 T,” *Radiographics*, vol. 28, no. 7, pp. 1983–1998, 2008.

[14] E. M. Merkle, B. M. Dale, and E. K. Paulson, “Abdominal MR imaging at 3T,” *Magnetic Resonance Imaging Clinics of North America*, vol. 14, no. 1, pp. 17–26, 2006.

[15] M. Maas, D. M. J. Lambregts, M. J. Lahaye et al., “T-staging of rectal cancer: accuracy of 3.0 tesla MRI compared with 1.5 tesla,” *Abdominal Imaging*, vol. 37, no. 3, pp. 475–481, 2012.

[16] P. Q. Cai, Y. P. Wu, X. An et al., “Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer,” *European Radiology*, vol. 24, no. 11, pp. 2962–2970, 2014.

[17] T. Ullrich, M. Quentin, C. Oelers et al., “Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: a prospective comparison study of image quality,” *European Journal of Radiology*, vol. 90, Supplement C, pp. 192–197, 2017.

[18] R. G. H. Beets-Tan, D. M. J. Lambregts, M. Maas et al., “Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting,” *European Radiology*, vol. 28, no. 4, pp. 1465–1475, 2018.

[19] J. T. Ferrucci, “Advances in abdominal MR imaging,” *Radiographics*, vol. 18, no. 6, pp. 1569–1586, 1998.

[20] H. Jara, M. A. Barish, E. K. Yucel, E. R. Melhem, S. Hussain, and J. T. Ferrucci, “MR hydrography: theory and practice of static fluid imaging,” *AJR American Journal of Roentgenology*, vol. 170, no. 4, pp. 873–882, 1998.

[21] F. Regan, J. Cavaluzzi, and B. Nguyen, “Fast MR abdominal imaging using the HASTE sequence,” *AJR American Journal of Roentgenology*, vol. 170, no. 6, pp. 1471–1476, 1998.

[22] X. Wang, A. Pirasteh, J. Brugarolas et al., “Whole-body MRI for metastatic cancer detection using T2-weighted imaging with fat and fluid suppression,” *Magnetic Resonance in Medicine*, vol. 80, no. 4, pp. 1402–1415, 2018.

[23] E. Kluza, E. D. Rozeboom, M. Maas et al., “T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer,” *European Radiology*, vol. 23, no. 1, pp. 253–261, 2013.

[24] Q. Xu, Y. Xu, H. Sun et al., “Quantitative intravoxel incoherent motion parameters derived from whole-tumor volume for assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer,” *Journal of Magnetic Resonance Imaging*, vol. 48, no. 1, pp. 248–258, 2018.

[25] S. H. Kim, J. Y. Lee, J. M. Lee, J. K. Han, and B. I. Choi, “Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer,” *European Radiology*, vol. 21, no. 5, pp. 987–995, 2011.